Literature DB >> 11893619

Volume expansion during acute angiotensin II receptor (AT(1)) blockade and NOS inhibition in conscious dogs.

Jens Lundbaek Andersen1, Niels C F Sandgaard, Peter Bie.   

Abstract

The responses to AT(1)-receptor blockade (candesartan 1 mg/kg) and to concomitant volume expansion (saline 35 ml/kg for 90 min) with and without nitric oxide synthase (NOS) inhibition (N(G)-nitro-L-arginine methyl ester 30 microg small middle dot kg(-1) small middle dot min(-1)) were investigated in separate experiments in normal dogs. AT(1) blockade decreased arterial pressure (106 +/- 4 to 96 +/- 5 mmHg) and increased glomerular filtration rate (GFR) by 17% and sodium excretion threefold. NOS inhibition increased arterial pressure (103 +/- 3 to 116 +/- 3 mmHg) and decreased GFR by 21% and reduced sodium excretion by some 80%. Volume expansion increased arterial pressure significantly in all series involving this procedure, most pronounced during combined AT(1) blockade and NOS inhibition (21 +/- 4 mmHg). Volume expansion during AT(1) blockade elicited marked natriuresis (26 +/- 11 to 274 +/- 55 micromol/min) that was severely reduced by concomitant NOS inhibition (10 +/- 3 to 45 +/- 11 micromol/min), but still much larger than that seen with volume expansion during NOS inhibition alone (2 +/- 1 to 23 +/- 7 micromol/min). Volume expansion during AT(1) blockade increased GFR (+30%), less so during combined AT(1) blockade and NOS inhibition (+13%), but it did not increase GFR significantly (P = 0.07) during NOS inhibition alone. Plasma ANG II increased greater than sevenfold with AT(1) blockade and doubled with NOS inhibition (paired t-test, P < 0.05), whereas it decreased by 50-80% during volume expansion irrespective of pretreatment, i.e., during NOS inhibition, volume expansion did not generate subnormal plasma ANG II concentrations. In conclusion, 1) acute AT(1) blockade leads to hyperfiltration, natriuresis, and hyperresponsiveness to volume expansion, 2) these responses are >85% inhibitable by unspecific NOS inhibition, and 3) NOS inhibition alone is followed by increases in plasma ANG II, hypofiltration, and severe antinatriuresis that may be counterbalanced but not overwhelmed by volume expansion. Thus NOS inhibition virtually abolishes the volume expansion natriuresis, at least in part, due to the lack of appropriate inhibition of the renin-angiotensin-aldosterone system.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11893619     DOI: 10.1152/ajpregu.00665.2000

Source DB:  PubMed          Journal:  Am J Physiol Regul Integr Comp Physiol        ISSN: 0363-6119            Impact factor:   3.619


  5 in total

1.  In vivo investigation of estrogen regulation of adrenal and renal angiotensin (AT1) receptor expression by PET.

Authors:  Taofeek K Owonikoko; Maria E Fabucci; Philip R Brown; Nighat Nisar; John Hilton; William B Mathews; Hayden T Ravert; Paige Rauseo; Kathryn Sandberg; Robert F Dannals; Zsolt Szabo
Journal:  J Nucl Med       Date:  2004-01       Impact factor: 10.057

2.  Effects of nitric oxide inhibition by methylene blue in cirrhotic patients with ascites.

Authors:  Georgios Kalambokis; Michalis Economou; Andreas Fotopoulos; Jihad Al Bokharhii; Pappas Christos; Kosta Paraskevi; Papadimitriou Konstantinos; Afroditi Katsaraki; Epameinondas V Tsianos
Journal:  Dig Dis Sci       Date:  2005-10       Impact factor: 3.199

3.  Mechanisms of acute natriuresis in normal humans on low sodium diet.

Authors:  M S Rasmussen; J A Simonsen; N C F Sandgaard; P F Høilund-Carlsen; P Bie
Journal:  J Physiol       Date:  2003-01-15       Impact factor: 5.182

4.  Angiotensin II Type 1 Receptors and Systemic Hemodynamic and Renal Responses to Stress and Altered Blood Volume in Conscious Rabbits.

Authors:  Tony B Xu; Gabriela A Eppel; Geoffrey A Head; Roger G Evans
Journal:  Front Physiol       Date:  2011-07-19       Impact factor: 4.566

5.  Renal effects of angiotensin II in the newborn period: role of type 1 and type 2 receptors.

Authors:  Angela E Vinturache; Francine G Smith
Journal:  BMC Physiol       Date:  2016-04-18
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.